ENYO Pharma has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. ENYO Pharma has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.
MIMESIS NEWSLETTER #1, April 2017
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
ENYO Pharma is pleased to announce the initiation of a collaboration with the group of Professor Patrice André (Inserm U1111, Lyon, France) to develop a deeper understanding of how FXR agonists inhibit the replication cycle of Hepatitis B (HBV). In addition to identifying opportunities for new anti-HBV therapeutics, this collaboration will strengthen understanding of the mode of action of EYP001, ENYO’s lead compound. EYP001 is a highly selective FXR modulator that reduces the HBV cccDNA reservoir,
ENYO Pharma has received the 10 M€ Tranche 2 of its Series A investment. The Board of Directors unanimously requested the Investors release this second Tranche of the 22 M€ Series A which closed in January 2016. This release is a response to several successfully achieved milestones, most importantly the Board decision to initiate Phase 1b in chronically infected, HBV patients. The first patients enrolment is planned for Q2 2017.